Hengehold Capital Management’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $354K | Sell |
916
-51
| -5% | -$18.9K | 0.03% | 169 |
|
|
2026
Q1 | $283K | Buy |
967
+1
| +0.1% | +$329 | 0.02% | 176 |
|
|
2025
Q4 | $339K | Hold |
966
| – | – | 0.03% | 172 |
|
|
2025
Q3 | $312K | Sell |
966
-144
| -13% | -$44.8K | 0.03% | 177 |
|
|
2025
Q2 | $432K | Buy |
1,110
+1
| +0.1% | +$402 | 0.04% | 145 |
|
|
2025
Q1 | $482K | Buy |
1,109
+1
| +0.1% | +$401 | 0.05% | 129 |
|
|
2024
Q4 | $409K | Buy |
1,108
+20
| +2% | +$8.37K | 0.04% | 136 |
|
|
2024
Q3 | $566K | Buy |
1,088
+34
| +3% | +$18.2K | 0.05% | 112 |
|
|
2024
Q2 | $571K | Buy |
1,054
+36
| +4% | +$19K | 0.06% | 105 |
|
|
2024
Q1 | $528K | Buy |
1,018
+1
| +0.1% | +$497 | 0.06% | 111 |
|
|
2023
Q4 | $479K | Buy |
1,017
+1
| +0.1% | +$462 | 0.06% | 111 |
|
|
2023
Q3 | $442K | Hold |
1,016
| – | – | 0.06% | 109 |
|
|
2023
Q2 | $451K | Buy |
1,016
+1
| +0.1% | +$461 | 0.06% | 108 |
|
|
2023
Q1 | $467K | Buy |
1,015
+1
| +0.1% | +$476 | 0.06% | 104 |
|
|
2022
Q4 | $520K | Hold |
1,014
| – | – | 0.07% | 98 |
|
|
2022
Q3 | $461K | Buy |
1,014
+1
| +0.1% | +$478 | 0.07% | 90 |
|
|
2022
Q2 | $489K | Buy |
1,013
+1
| +0.1% | +$495 | 0.07% | 84 |
|
|
2022
Q1 | $497K | Buy |
1,012
+31
| +3% | +$14.2K | 0.07% | 88 |
|
|
2021
Q4 | $455K | Sell |
981
-9
| -0.9% | -$3.79K | 0.06% | 103 |
|
|
2021
Q3 | $369K | Buy |
990
+1
| +0.1% | +$380 | 0.05% | 112 |
|
|
2021
Q2 | $378K | Sell |
989
-40
| -4% | -$15.3K | 0.05% | 107 |
|
|
2021
Q1 | $369K | Buy |
1,029
+1
| +0.1% | +$322 | 0.05% | 103 |
|
|
2020
Q4 | $330K | Buy |
1,028
+1
| +0.1% | +$307 | 0.05% | 107 |
|
|
2020
Q3 | $276K | Hold |
1,027
| – | – | 0.04% | 107 |
|
|
2020
Q2 | $270K | Sell |
1,027
-11
| -1% | -$2.94K | 0.05% | 105 |
|
|
2020
Q1 | $236K | Sell |
1,038
-1,131
| -52% | -$308K | 0.05% | 98 |
|
|
2019
Q4 | $655K | Sell |
2,169
-1,061
| -33% | -$292K | 0.11% | 67 |
|
|
2019
Q3 | $775K | Buy |
3,230
+2,185
| +209% | +$599K | 0.14% | 58 |
|
|
2019
Q2 | $295K | Hold |
1,045
| – | – | 0.06% | 101 |
|
|
2019
Q1 | $300K | Buy |
1,045
+28
| +3% | +$8.1K | 0.07% | 95 |
|
|
2018
Q4 | $267K | Sell |
1,017
-93
| -8% | -$25.6K | 0.09% | 90 |
|
|
2018
Q3 | $304K | Buy |
1,110
+30
| +3% | +$7.79K | 0.08% | 86 |
|
|
2018
Q2 | $257K | Buy |
1,080
+158
| +17% | +$36.6K | 0.07% | 98 |
|
|
2018
Q1 | $203K | Hold |
922
| – | – | 0.05% | 109 |
|
|
2017
Q4 | $207K | Buy |
+922
| New | +$196K | 0.05% | 109 |
|
Other funds holding ELV
Hengehold Capital Management's ELV Position: Q2 2026 in Review
Hengehold Capital Management reduced its Elevance Health (ELV) stake by 5.3% in Q2 2026, selling an estimated $18.9K and leaving 916 shares worth $354K. The position accounts for 0.03% of the portfolio, ranked #169.
Hengehold Capital Management first reported a position in ELV in Q4 2017 and has held it in 35 quarters since. The position peaked at $775K in Q3 2019. 960 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Hengehold Capital Management held 916 shares of Elevance Health worth $354K as of Q2 2026.
- Hengehold Capital Management sold 51 Elevance Health shares in Q2 2026, an estimated $18.9K.
- Elevance Health made up 0.03% of Hengehold Capital Management's portfolio in Q2 2026, its #169 holding.
- Hengehold Capital Management first reported a position in Elevance Health in Q4 2017 and has held it in 35 quarters since.
- Hengehold Capital Management's Elevance Health position peaked at $775K in Q3 2019.
- 960 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Hengehold Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.